AIM: The aim of this study was to determine the prevalence of erectile dysfunction (ED), testosterone deficiency syndrome (TDS), and metabolic syndrome in patients with abdominal obesity (AO) and the prevalence of morbidity at different levels of testosterone (TST). BACKGROUND: Male sex hormones play an important role in ED and variety of TDS and may have influence on the development of metabolic syndrome. The number of men with AO which constitutes a serious health risk is continuously growing. Currently, there are different views that TST levels are already insufficient, and the patient should benefit from treatment. OBJECTIVES: This study examined the association between ED, testosterone level and metabolic syndrome in men with AO. DESIGN, SETTING, AND PARTICIPANTS: The study was carried out in an outpatient urology center of Urology Clinic and Obesity Center of the Clinic of Internal Medicine. There were 167 participants—men with AO which were examined as part of preventive examination. METHODS: Hormonal, a complete urological and internal evaluation was carried out in every patient. RESULTS AND LIMITATIONS: We found some degree of ED in 73% (122/167) in men with AO. The TST levels below 14 nmol/l had of these 122 patients 84 patients (68.9%) and 49 patients (40.2%) below 10 nmol/l. In this group of patients, we found 103/167 patients (61.7%) with metabolic syndrome. When we compared TST level and morbidity, we found significantly more patients with diabetes mellitus (DM), hypertension and dyslipidemia in group with TST below 10 nmol/l. We also found difference in the levels of HDL cholesterol and triglycerides in the group of patients with TST 10–14 and over 14 nmol/l. CONCLUSION: Patients over 40 years of age with AO and ED should also be examined for TDS and metabolic syndrome. In this group of patients we found that 113/167 patients (67.6%) had total TST below 14 nmol/l, and sufficient level of TST seems to be above this level.
AIM: The aim of this study was to determine the prevalence of erectile dysfunction (ED), testosterone deficiency syndrome (TDS), and metabolic syndrome in patients with abdominal obesity (AO) and the prevalence of morbidity at different levels of testosterone (TST). BACKGROUND: Male sex hormones play an important role in ED and variety of TDS and may have influence on the development of metabolic syndrome. The number of men with AO which constitutes a serious health risk is continuously growing. Currently, there are different views that TST levels are already insufficient, and the patient should benefit from treatment. OBJECTIVES: This study examined the association between ED, testosterone level and metabolic syndrome in men with AO. DESIGN, SETTING, AND PARTICIPANTS: The study was carried out in an outpatient urology center of Urology Clinic and Obesity Center of the Clinic of Internal Medicine. There were 167 participants—men with AO which were examined as part of preventive examination. METHODS: Hormonal, a complete urological and internal evaluation was carried out in every patient. RESULTS AND LIMITATIONS: We found some degree of ED in 73% (122/167) in men with AO. The TST levels below 14 nmol/l had of these 122 patients 84 patients (68.9%) and 49 patients (40.2%) below 10 nmol/l. In this group of patients, we found 103/167 patients (61.7%) with metabolic syndrome. When we compared TST level and morbidity, we found significantly more patients with diabetes mellitus (DM), hypertension and dyslipidemia in group with TST below 10 nmol/l. We also found difference in the levels of HDL cholesterol and triglycerides in the group of patients with TST 10–14 and over 14 nmol/l. CONCLUSION:Patients over 40 years of age with AO and ED should also be examined for TDS and metabolic syndrome. In this group of patients we found that 113/167 patients (67.6%) had total TST below 14 nmol/l, and sufficient level of TST seems to be above this level.
Authors: Juuso Mäkinen; Mikko J Järvisalo; Pasi Pöllänen; Antti Perheentupa; Kerttu Irjala; Markku Koskenvuo; Juha Mäkinen; Ilpo Huhtaniemi; Olli T Raitakari Journal: J Am Coll Cardiol Date: 2005-05-17 Impact factor: 24.094
Authors: E Nieschlag; R Swerdloff; H M Behre; L J Gooren; J M Kaufman; J-J Legros; B Lunenfeld; J E Morley; C Schulman; C Wang; W Weidner; F C W Wu Journal: Eur Urol Date: 2005-07 Impact factor: 20.096
Authors: Kay-Tee Khaw; Mitch Dowsett; Elizabeth Folkerd; Sheila Bingham; Nicholas Wareham; Robert Luben; Ailsa Welch; Nicholas Day Journal: Circulation Date: 2007-11-26 Impact factor: 29.690
Authors: F Parazzini; F Menchini Fabris; A Bortolotti; A Calabrò; L Chatenoud; E Colli; M Landoni; M Lavezzari; P Turchi; A Sessa; V Mirone Journal: Eur Urol Date: 2000-01 Impact factor: 20.096
Authors: David E Laaksonen; Leo Niskanen; Kari Punnonen; Kristiina Nyyssönen; Tomi-Pekka Tuomainen; Veli-Pekka Valkonen; Riitta Salonen; Jukka T Salonen Journal: Diabetes Care Date: 2004-05 Impact factor: 19.112
Authors: Giovanni Corona; Edoardo Mannucci; Luisa Petrone; Claude Schulman; Giancarlo Balercia; Alessandra D Fisher; Valerio Chiarini; Gianni Forti; Mario Maggi Journal: J Sex Med Date: 2007-05 Impact factor: 3.802
Authors: Adam C Millar; Adrian N C Lau; George Tomlinson; Alan Kraguljac; David L Simel; Allan S Detsky; Lorraine L Lipscombe Journal: CMAJ Date: 2016-06-20 Impact factor: 8.262
Authors: P Šiarnik; M Jurík; M Hardoňová; K Klobučníková; J Veverka; P Šurda; P Turčáni; B Kollár Journal: Physiol Res Date: 2020-09-09 Impact factor: 1.881